Showing 2381-2390 of 4063 results for "".
- Ivantis Announces 3-Year Results from FDA Clinical Trial Demonstrating Long-Term Reduction of Severe Major Surgeries for Glaucoma Patientshttps://modernod.com/news/ivantis-announces-3-year-results-from-fda-clinical-trial-demonstrating-long-term-reduction-of-severe-major-surgeries-for-glaucoma-patients/2476534/Ivantis, developer of the Hydrus Microstent, announced the 3-year results from the HORIZON pivotal study. The 2-year results, which were the foundation of FDA approval, were presented in November 2017, and were recently published in the journal Ophthalmology.
- Avellino Labs to Provide Corporate and Technology Updates at OIS and ASCRS in San Diegohttps://modernod.com/news/avellino-labs-to-provide-corporate-and-technology-updates-at-ois-and-ascrs-in-san-diego/2476522/Executives from Avellino Labs will be presenting at several events during the American Society of Cataract and Refractive Surgery annual meeting at the San Diego Convention Center and nearby venues, May 2-5, 2019. Known for its successful introduction of the world’s first DNA test to
- Allergan to Showcase New Data at ARVOhttps://modernod.com/news/allergan-to-showcase-new-data-at-arvo/2476496/Allergan will present new data at the Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO) to be held in Vancouver, British Columbia from April 28 – May 2. Data will include three paper presentations on the company’s ophthalmology pipeline including
- ProtoKinetix AAGP in Phase 3 Retinal Replacement Programhttps://modernod.com/news/protokinetix-aagp-in-phase-3-retinal-replacement-program/2476493/ProtoKinetix updated its stockholders regarding phase 3 of testing using AAGP in retinal cell replacement therapy at the University of British Columbia. The study is now using 2 animal models and a significantly larger number of animals in both control and AAGP treated groups for a longer
- GenSight Biologics Reports Positive Follow-Up Results of Phase 3 Trial in LHONhttps://modernod.com/news/gensight-biologics-reports-positive-follow-up-results-of-phase-3-trial-in-lhon/2476475/GenSight Biologics announced results from the second scheduled readout, at week 72, of the RESCUE phase 3 clinical trial evaluating the safety and efficacy of a single intravitreal injection of GS010 (rAAV2/2-ND4) in 39 subjects whose visual loss due to 11778-ND4 Leber Hereditar
- Results of Lumega-Z Data to be Presented at ARVOhttps://modernod.com/news/results-of-lumega-z-data-to-be-presented-at-arvo/2476474/Guardion Health Sciences Scientific Advisory Board member William Sponsel, MD, will be presenting an abstract at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting in Vancouver, Canada, which will be held from April 28, 2019 to May 2, 2019. The abstract is titled
- SilkTech Biopharmaceuticals’ IND Submission Cleared by FDA for Dry Eye Drophttps://modernod.com/news/silktech-biopharmaceuticals-ind-submission-cleared-by-fda-phase-2-clinical-trial-initiated-for-patients-with-dry-eye-disease/2476469/SilkTech Biopharmaceuticals announced the company has received clearance of its investigational new drug (IND) submission with the FDA for its SDP-4 eye drop product. In addition, the company has initiated a phase 2 clinical trial for its first-in-class drug to assess the safety and efficacy of t
- NovaBay Pharmaceuticals Announces Investments of $5 Million to Support US Avenova Commercialization Strategyhttps://modernod.com/news/novabay-pharmaceuticals-announces-investments-of-5-million-to-support-us-avenova-commercialization-strategy/2476424/NovaBay Pharmaceuticals announced investments totaling $5 million to support the recent strategic shift in its US commercialization strategy aimed at driving growth in Avenova sales while maintaining cost effectiveness. The investments include a convertible loan of $2 million from Ascendia
- ReNeuron Announces Retinal Clinical Trial Progresses to Next Stagehttps://modernod.com/news/reneuron-announces-retinal-clinical-trial-progresses-to-next-stage/2476391/ReNeuron Group has announced a further update on progress with the ongoing phase 1/2 clinical trial in the US of its hRPC cell therapy candidate in retinitis pigmentosa (RP). The company reported that, following a positive Data Safety Monitoring Board (DSMB) review of the clinical data fro
- AbbVie’s Humira (Adalimumab) Approved by Health Canada to Treat Pediatric Patients with Chronic Noninfectious Anterior Uveitishttps://modernod.com/news/abbvies-humira-adalimumab-approved-by-health-canada-to-treat-pediatric-patients-with-chronic-noninfectious-anterior-uveitis/2476279/AbbVie announced that Health Canada has approved Humira (adalimumab) for the treatment of chronic noninfectious anterior uveitis in pediatric patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropr